Industry & Policy News

[Washington University School of Medicine in St. Louis] Robert Schreiber, PhD, of Washington University School of Medicine in St. Louis, is the 2024 Senior Scientist Winner of the Innovators in Science Award. The award recognizes his outstanding contributions to the field of cancer immunology.

[Korro Bio, Inc.] Korro Bio, Inc. has nominated its first development candidate, KRRO-110, for the potential treatment of AATD. KRRO-110 is a proprietary RNA editing oligonucleotide delivered to liver cells using clinically validated LNP technology licensed from Genevant.

[Gallant Therapeutics (Globe Newswire)] Gallant Therapeutics announced the launch of a pivotal study to evaluate the safety and efficacy of its novel allogeneic stem cell therapy candidate to support FDA conditional approval in cats with refractory feline chronic gingivostomatitis, the JEDI study.

[Bristol Myers Squibb] Bristol Myers Squibb announced the Phase III CheckMate -8HW trial evaluating Opdivo plus Yervoy compared to investigator’s choice of chemotherapy as a first-line treatment for patients with microsatellite instability–high or mismatch repair deficient metastatic colorectal cancer met the dual primary endpoint of progression-free survival.

[UNC Gillings School of Global Public Health] The American Cancer Society has awarded a five-year, $1.2 million Team Science grant to a group of UNC-Chapel Hill researchers who will develop new methods to measure and map cancer screening across North Carolina.

[The Guardian] Leading scientists are calling for a change in the law to help IVF patients donate unused embryos to biomedical research after a collapse in donations over the past 15 years.